Management of persistent ductus arteriosus in very premature neonates. Results of the French TRIOCAPI trial, perspectives for clinicians, and subsequent studies on this topic
2021
Cambonie, G. | Clyman, Ronald | Rozé, J.-C. | Pôle Femme Mère Enfant [CHRU Montpellier] ; Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) | University of California [San Francisco] (UC San Francisco) ; University of California (UC) | Département de pédiatrie [CHU Nantes] ; Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes) | Physiopathologie des Adaptations Nutritionnelles (PhAN) ; Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE) ; Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Over the past four decades, the management of persistent ductus arteriosus (PDA) in newborns has remained a hotly debated topic and there is currently no consensus on who, when, and how to treat. While some authors argue that a PDA is an innocent bystander, making treatment unnecessary and potentially dangerous [1], others are concerned about the potential harmful effects of a PDA, which include pulmonary hemorrhage, bronchopulmonary dysplasia (BPD), hypotension, intraventricular hemorrhage (IVH), necrotizing enterocolitis, and mortality [2]. Current PDA treatment strategies vary from an early pharmacologic approach to a conservative approach, with specific criteria for late pharmacologic treatmen
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Institut national de la recherche agronomique